Compare INO & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INO | ECOR |
|---|---|---|
| Founded | 1979 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.5M | 81.0M |
| IPO Year | 1999 | 2018 |
| Metric | INO | ECOR |
|---|---|---|
| Price | $1.10 | $8.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $6.75 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 1.5M | 124.9K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.18 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $42,220,086.00 | $32,032,000.00 |
| Revenue This Year | $20,156.19 | $33.60 |
| Revenue Next Year | $421.95 | $30.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 19.37 | ★ 27.20 |
| 52 Week Low | $1.03 | $4.16 |
| 52 Week High | $2.86 | $10.50 |
| Indicator | INO | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 43.35 | 52.22 |
| Support Level | $1.03 | $8.55 |
| Resistance Level | $1.23 | $10.43 |
| Average True Range (ATR) | 0.05 | 0.91 |
| MACD | 0.01 | -0.19 |
| Stochastic Oscillator | 45.00 | 46.46 |
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.